Your session is about to expire
← Back to Search
Virus Vaccine
SARS-COV2 Pfizer Vaccine for Coronavirus
Phase < 1
Waitlist Available
Led By Rachna Shroff, MD
Research Sponsored by University of Arizona
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months
Awards & highlights
Study Summary
Explore the effects on immune response to include a potential third vaccine for the cancer cohort.
Eligible Conditions
- Coronavirus
- Cancer
- Vaccine Response Impaired
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 3 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Immune response
Secondary outcome measures
Adverse events
Trial Design
1Treatment groups
Experimental Treatment
Group I: 3rd COVID-19 vaccine (2nd booster)Experimental Treatment1 Intervention
Patients who were a part of the non-interventional portion of the study are eligible to receive a third COVID-19 Pfizer vaccine.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
SARS-COV2 Pfizer Vaccine
2021
Completed Early Phase 1
~20
Find a Location
Who is running the clinical trial?
University of ArizonaLead Sponsor
514 Previous Clinical Trials
148,251 Total Patients Enrolled
Rachna Shroff, MDPrincipal InvestigatorUniversity of Arizona
1 Previous Clinical Trials
29 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger